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ABSTRACT 
Objective: The objective of this study was to evaluate sustained release matrix tablets of metformin formulated using Detarium microcarpum gum 
(DMG) as the matrix polymer. 
Methods: DMG was produced by acetone desolvation of the filtrate obtained by maceration of powdered seeds of Detarium microcarpum in distilled 
water. Metformin matrix tablets were prepared by direct compression technique using DMG or sodium carboxymethylcellulose (NaCMC) alone, or 
their combinations as the polymer matrix. The tablets were evaluated for hardness, friability, weight uniformity, drug content, swelling 
behaviour and in vitro dissolution. They were compared to a marketed product. 
Results: The results of the evaluation showed that the tablets had physical characteristics that were within the acceptable limits and were 
comparable to the marketed product. They include hardness (7.13±1.99 to 13.17±1.59 Kgf), friability (0.40 to 0.80%), and drug content (95.11 to 
104.17%). Formulations MTF2 (30% DMG) and MTF6 (20% DMG and 10% NaCMC) showed good sustained release behaviour, as they released 
75% of the drug within 7 to 9 h and 100% release in more than 12 h. 
Conclusion: DMG alone or with NaCMC was successfully used to formulate sustained release metformin matrix tablets that were comparable to the 
marketed product. 
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INTRODUCTION 
Extended or sustained-release products are formulated to make the 
drug available over an extended period after ingestion. This allows a 
reduction in dosing frequency compared to a drug presented as a 
conventional dosage form [1-3]. Properly designed sustained release 
dosage form provides benefits such as low-cost, simple processing, 
improved efficacy, reduced adverse events, flexibility in terms of the 
range of release profiles attainable, increased convenience and 
patient compliance [4-6]. Extended-release can be achieved through 
several methods such as matrix formation [7], floating drug delivery 
system [8], mucoadhesive drug delivery system [9], and 
microencapsulation [10], but the hydrophilic matrix is one of the 
least complicated methods for formulating an extended-release 
preparation. Hydrophilic matrix polymers include hydroxypropyl 
methylcellulose (HPMC), hydroxyethylcellulose (HEC), hydroxypropyl 
cellulose (HPC) and sodium carboxymethylcellulose (NaCMC). The 
transport phenomena involved in the drug release from hydrophilic 
matrices are complex because their microstructure and 
macrostructure, when exposed to water, are strongly time-dependent. 
When they come in contact with the gastrointestinal fluid, they swell, 
gel, and ultimately dissolve slowly (matrix erosion) [2, 6, 7, 11]. The 
gel forms a viscous layer, which acts as a protective barrier that 
regulates the influx of water and the efflux of the drug in solution. The 
dissolution can be diffusion controlled depending on the molecular 
weight and thickness of the diffusion boundary layer [2, 3].  
Detarium microcarpum, Guill. and Perr. (Fabaceae) is a wild plant 
found in some parts of the semi-arid sub-Saharan and tropical zones 
of Africa. The seeds are edible and are used for the thickening of 
soups in some parts of Nigeria. It possesses unique characteristic 
behaviour in hot water, displaying different degrees of the 
viscoelastic properties. It has been reported to contain a high 
concentration of water-soluble non-starch polysaccharide, which is 
mainly xyloglucan [12].  
Metformin is an oral anti-hyperglycemic drug used in the 
management of non-insulin-dependent diabetes mellitus (NIDDM). 
It is the only available biguanide. It improves glucose tolerance in 
NIDDM subjects, lowering both basal and postprandial plasma 
glucose. It reduces hepatic glucose production, lowers intestinal 
absorption of glucose, and increases insulin sensitivity. Metformin in 
contrast to sulfonylureas, does not cause hypoglycemia in either 
diabetic or nondiabetic subjects and does not produce 
hyperinsulinemia [13]. Metformin is a highly hydrophilic drug and 
its oral bioavailability is 50 to 60% [14, 15]. It has a plasma 
elimination half-life of 6.2 h with a peak plasma concentration of 4.8 
h [14]. 
The aim of this study was to evaluate sustained release matrix 
tablets of metformin formulated using Detarium microcarpum gum 
as the polymer matrix former. Detarium microcarpum is found 
abundantly in the Southeast region of Nigeria and the use of the gum 
in matrix tablet production will result in great economic benefit to 
the region. 
MATERIALS AND METHODS 
Materials 
All the chemicals used were of analytical grade. They include 
metformin (Kores Chemical Ltd, India), microcrystalline cellulose 
(Avicel-PH 101) (FMC Biopolymer, Philadelphia, USA), sodium 
carboxymethylcellulose (BDH Chemicals Ltd Poole England), 
acetone (Guangxing Guanghua Chemical, China) and magnesium 
stearate (Kem Light Chemicals Ltd, Mumbai, India), potassium 
dihydrogen orthophosphate, dipotassium hydrogen phosphate (BDH 
Chemicals Ltd Poole England), hydrochloric acid (JHD, Guangdong 
Guanghua Chemical Factory Co. Ltd., Shanfua, Guangdong, China). 
Methods 
The study was carried out by isolation of DMG, drug–excipients 
compatibility studies, drug/excipients-mix micromeritics studies, 
preparation of sustained-release metformin matrix tablets, 
evaluation of sustained-release metformin matrix tablets, kinetics 
and mechanism of drug release, and analysis of data. 
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Isolation of Detarium microcarpum gum 
Seeds of Detarium microcarpum were bought from Ogbete market in 
Enugu, Nigeria. They were identified by Mr. Felix Nwafor a 
taxonomist in the Department of Pharmacognosy and 
Environmental Medicine, Faculty of Pharmaceutical Sciences, 
University of Nigeria, Nsukka, Nigeria. The sample was deposited in 
the herbarium with voucher number PCG/UNN/0067. The gum was 
extracted using the method of [16] with slight modification. The 
seeds were dried and ground to powder. A 200 g quantity of the 
powder was macerated in 1.5 litres of distilled water for 24 h. The 
filtrate was precipitated with equal volumes of acetone. The 
precipitated gum was washed twice with acetone, air-dried and kept 
in an airtight container. The percentage yield of the gum was 
calculated using equation 1.  
Percentage yield (%) = 
                      ( )
                                 ( )
 X 100% …. (1) 
Drug–excipients compatibility studies 
This was evaluated using Fourier transformed infrared (FTIR) 
spectroscopy operating between 4000 and 600 cm-1. Sampling was 
done using the potassium bromide pellets technique. 
Micromeritics of the drug/excipients mix 
The bulk density and tapped density of the drug/excipient mix for 
the different formulations were determined and were used to 
calculate the Carr’s index and Hausner’s ratio. 
Bulk density 
A 10 g quantity of the metformin–excipient mix was weighed and 
put in a 25 ml measuring cylinder. The volume was measured and 
recorded as the bulk volume. The bulk density was calculated using 
equation 2. 
Bulk density =  
weight of powder mix (g)
Bulk volume of the powder mix (ml)
…… (2) 
Tapped density 
The metformin powder mix contained in the 25 ml measuring cylinder 
was tapped 100 times and the new volume was recorded as the tapped 
volume. The Tapped density was calculated using equation 3. 
Tapped density =  
Weight of the powder mix (g)
Tapped volume of the powder mix (ml)
…. (3) 
Carr’s index 
This was calculated using equation 4. 
Carr′s index =  
Tapped density bulk density
Tapped density
 X 100%..... (4) 
Hausner’s ratio 





Angle of repose 
The funnel method was used. The drug-excipient powder-mix was 
poured through a funnel clamped to a retort stand to form a heap 
(cone) at the base. The angle the powder-mix made with the base, 
angle of repose (ɵ) was calculated using equation 6.  




Where h = height of the heap (cone) and r = radius of the cone.  
Preparation of sustained-release metformin matrix tablets 
The metformin matrix tablets were formulated by the direct 
compression method using the formula on table 1. Metformin was 
mixed properly with DMG or NaCMC or a combination of the two and 
MCC. Talc and magnesium stearate were added and mixed lightly for 
a short period. The metformin/excipient mix was compressed at a 
predetermined pressure using a single punch tablet machine with 13 
mm punches (Manesty Machine Ltd, B3B Liverpool, England). 
 
Table 1: Composition of sustained-release metformin matrix tablets 
Ingredients MTF1 MTF2 MTF3 MTF4 MTF5 MTF6 
Metformin (mg) 500 500 500 500 500 500 
DMG (mg) 160 240 80 120 160 - 
NaCMC (mg) - - 160 120 80 240 
MCC (mg) 116 36 36 36 36 36 
Talc (mg) 16 16 16 16 16 16 
Magnesium stearate (mg) 8 8 8 8 8 8 
Total (mg) 800 800 800 800 800 800 
 
Evaluation of sustained-release metformin matrix tablets 
The formulated tablets were evaluated based on their physical 
characteristics and compared with a marketed product, Glucodix 
ER® (produced by Stallion laboratories, India, and marketed in 
Nigeria by Codix Pharma.) used as the control.  
Uniformity of weight 
Twenty tablets were randomly picked from the formulations and 
weighed individually. The difference between their weights and 
their average weight was recorded and used in calculating the 
percentage weight deviation. 
Hardness 
Five tablets were randomly selected from the formulations and tested 
for hardness using a digital tablet hardness test apparatus (Veego 
tablet test apparatus, India). The readings displayed were recorded. 
Friability 
Ten tablets selected randomly from the formulation were weighed 
together and placed in the drum of a friabilator (Veego friability test 
apparatus, India). They were tumbled for 4 min at 25 rpm, de-
dusted, and reweighed. Friability was calculated using equation 7 
Friability =  
(initial weight  inal weight)
initial weight
X 100%…. (7) 
Thickness and diameter 
Five tablets were selected randomly and their thickness and 
diameter measured using the thickness and diameter functions 
respectively of a digital tablet hardness test apparatus (Veego 
Instruments, India). 
Drug content 
Ten tablets were randomly selected from each of the formulations, 
weighed, and crushed in a mortar with pestle, respectively. A 
quantity of powder that contained the equivalent of 100 mg of 
metformin was weighed and dissolved in 100 ml of 0.1N HCl. This 
was filtered through a 0.45-μm filter paper and the filtrate was 
diluted with 0.1 N HCl to obtain a 10 µg/ml solution. The drug 
content was analyzed spectrophotometrically at 233 nm using a 
Carry 60 UV-VIS spectrophotometer (Agilent Technologies, 
Malaysia). The drug content was determined by matching 
absorbance value obtained to the calibration curve of metformin. 
In vitro dissolution studies 
This was done using USP apparatus I (rotating basket). The 
metformin tablet was placed in the basket immersed in 900 ml of 0.1 
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N HCl as a dissolution medium in the dissolution chamber. The 
basket was rotated at 100 rpm and maintained at a temperature of 
37±1 °C. Samples (5 ml) were withdrawn after 0.5, 1, and 2 h and 
replaced with a pre-heated fresh dissolution medium. The samples 
were filtered, appropriately diluted, and analyzed using a Carry 60 
UV–VIS spectrophotometer (Agilent Technologies, Malaysia) at 233 
nm. After 2 h, the dissolution medium was changed to phosphate 
buffer pH 6.8, and samples were taken hourly for 10 h.  
Swelling studies  
The method used was a slight modification of the method used by 
[17]. Tablets were weighed individually (W1) and placed in 
respective Petri dishes. A 25 ml quantity of 0.1N HCl was added to 
each Petri dish. After 1 h, the 0.1 N HCl was drained and the Petri 
dish dried using tissue paper. The swollen tablets were reweighed 
(W2). This process was repeated after 3, 6, 9, and 12 h, respectively. 
The swelling index (S. I) was calculated using equation 8. 
Swelling index =  
(W2 W1)
W1
X 100%..... (8) 
Where W2 = final weight of tablet and W1 = initial weight of tablet. 
Stability studies 
Tablets from the optimized formulation (MTF2) were stored in an 
airtight container and kept in a stability chamber for 3 mo at a 
temperature and relative humidity of 40 °C±2 °C/75% RH±5% RH. 
They were evaluated for hardness, friability and in vitro drug release. 
Kinetics and mechanism of drug release  
The kinetics and mechanism of the drug release from the tablets 
were assessed by fitting the drug release data to the following 
release kinetic models: Zero-order release model, First order release 
model, Higuchi square root model, Hixson-Crowell cube root model, 
and Korsmeyer–Peppas model [18-20] and the most appropriate 
model was chosen based on goodness of fit test [19].  
Analysis of data 
Statistical analysis was done using Microsoft Excel and SPSS version 
22.0. Data were analyzed by one–way ANOVA. Differences between 
means were assessed by a two-tailed Student’s t–test. P<0.05 was 
considered statistically significant. 
RESULTS AND DISCUSSION 
The percentage yield for DMG was 76.39±1.17%w/w. The yield was 
very high and this will make the cost of the gum to be low and 
affordable. 
Micromeritics 
The angle of repose, Hausner’s ratio and Carr’s index for the 
drug/excipient powder-mix were as shown on table 2. Angle of 
repose value of less than 25 indicates excellent flow [21] and the 
value obtained for all the formulations were below 25. Hausner ratio 
values of less than 1.25 indicate good flow, while greater than 1.25 
indicates poor flow. The flow for those between 1.25 and 1.5 can be 
improved by the addition of glidant [21]. Only formulation MTF6 had 
Hausner’s ratio value of less than 1.25, others were above 1.25 but 
below 1.5. The Carr’s index value of 18 to 21 indicates fair to 
passable flow, while 23 to 35 shows poor flow [21]. Apart from 
formulation MTF6 that had Carr’s index of 18.77±4.54, others had 
Carr’s index values of between 23.48±1.31 and 26.92±1.20. The flow 
properties of all the formulations could be improved by the addition 
of glidant such as 0.2% Aerosil. 
  
Table 2: Powder flow characteristics for the metformin/excipients mix 
Formulation code Angle of Repose ( °) Hausner’s ratio Carr’s index 
MTF1 24.76±0.94 1.31±0.00 23.81±0.00 
MTF2 23.85±0.84 1.37±0.02 26.92±1.20 
MTF3 21.43±0.00 1.31±0.02 23.48±1.31 
MTF4 21.79±2.27 1.31±0.00 23.81±0.00 
MTF5 24.58±1.13 1.31±0.04 23.61±2.08 
MTF6 18.75±0.34 1.23±0.07 18.77±4.54 
Notes: All data values are expressed as mean±SD, n = 3 
 
Evaluation of tablets 
The result shown in table 3 indicated that the friability values of 
tablets from all the formulations were below 1% and were within 
specification. Friability is a measure of the tablets' ability to withstand 
the abrasion that may occur during handling or transportation. 
Tablets from all the formulations had hardness values above 4 Kgf. 
Hardness shows the ability of the tablets to withstand mechanical 
shocks during further handling and transportation. Tablets having 
adequate hardness do not usually crack or break when subjected to 
moderate pressure. Hardness is dependent on the nature and 
concentration of binder (gum), nature, and concentration of 
disintegrant and on compression force applied [22]. 
Metformin tablets should contain between 95% and 105% of 
metformin active [23]. The drug contents for the different 
formulations were between 95.11% and 104.17%, and they were all 
within the specified limits. There was no significant difference 
(p<0.5) between the ideal drug content (100%) and that of the 
different formulations. When powders are properly mixed according 
to the tablet composition, the resultant tablets are usually of uniform 
weight and drug content.  
The mean tablet weights for the different formulations were shown 
in table 3. All the formulations had a percentage mean weight 
deviation of less than 5% and were within the specified limit. Tablets 
that weigh more than 250 mg should have a percentage mean weight 
deviation of not more than 5% [23]. 
 
Table 3: The physical characteristics of metformin matrix tablets 
Formulation code Friability 
(%) n=10 
Hardness (kgf)  
n=5 
Thickness (mm)  
n=5 
Diameter (mm)  
n=5 




MTF1 0.50 8.50±0.75 4.96±0.04 13.01±0.04 0.794±0.008 104.17 
MTF2 0.80 9.27±0.69 5.19±0.12 13.04±0.06 0.797±0.005 98.82 
MTF3 0.40 14.57±0.52 5.18±0.11 13.05±0.02 0.795±0.006 95.55 
MTF4 0.56 13.40±1.76 5.17±0.06 13.01±0.05 0.796±0.009 102.42 
MTF5 0.56 10.87±2.48 5.17±0.12 13.06±0.04 0.797±0.007 95.83 
MTF6 0.72 11.72±0.19  5.30±0.08 13.10±0.02 0.799±0.007 95.11 
Control 0.18 16.13±2.07 5.68±0.08 9.22±0.04 0.661±0.009 96.02 
Notes: all data (except friability and drug content), given as mean±SD 
Swelling studies 
The swelling index for the different formulations is shown on 
1. The swelling index for formulation MTF1 was 80% after 1 h
started to decline from 3 h. Matrix erosion sets in after 
12 h, about 70% of the matrix tablet structure h
swelling index for formulations MTF2 to MTF6 increased 
progressively until the 12th hour when there was a decline except 
for formulations MTF3 and MTF4. The control showed a progressive 
  
Fig. 1: Swelling behavior of sustained release metformin matrix tablets
sodium carboxymethyl cellulose, MTF1 (20% DMG), MTF2 (30% DMG), MTF3 (10% DMG/20% NaCMC), MTF4 (15% DMG/15% NaCMC), 
MTF5 (20% DMG/10% NaCMC), MTF6 (30% Na
In vitro dissolution studies 
The %drug release of metformin from the sustained release matrix 
tablets is shown in fig. 2. For formulation MTF1, 51.98% of the drug 
was released within 0.5 h. Seventy-five percent of the drug was 
released within 2 h and 100% within 8 h. This shows that 
formulation MTF1 could not be used for sustained release delivery 
of metformin. For formulations MTF2 to MTF6, the time for the 
release of 75% of the drug ranged from 3 to 11 h. The time for 100% 
  
Fig. 2: %Drug release from the sustained release metformin matrix tablets
NaCMC–sodium carboxymethyl cellulose, MTF1 (20% DMG), MTF2 (30% DMG), MTF3 (10% DMG/20% NaCMC), MTF4 (15% DMG/15% 
NaCMC), MTF5 (20% DMG/10% NaCMC), MTF6 (30% NaCMC)
Drug–excipient compatibility studies  
No significant shifts or reduction in the intensity of the FTIR bands 
of metformin hydrochloride were observed as shown in 
This showed that there was no incompatibility between metformin 
and DMG. Metformin shows characteristic bands at specif
of the FTIR spectrum [25]. As shown in fig. 
spectrum for metformin and that of metformin plus DMG showed 
typical bands at 3124.4 and 3118.5 cm–1 respectively due to N
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fig. 
, but it 
6 h and after 
as broken down. The 
increase in swelling index even at 12 h. Polymer m
containing gum that have long swelling time will have their 
medicaments released relatively slow [24]. Matrix tablets upon 
contact with water, hydrates, swells, and gels. The more the swelling 
time, the thicker the gel formed and this results
taken for the drug to diffuse across the gel. From the swelling studies 
result shown in fig. 1, it is expected that matrix tablets from 
formulations MTF2 to MTF6 will have strong release retardant 
property.
 (mean±SD, n=3), Key: DMG–Detariummicrocarpum
CMC) 
 
release was between 12 h and above. Formulations MTF2 and MTF6 
showed good sustained release behaviour, as they released 75% of 
the drug within 7 to 9 h and 100% release in more than 12 h. 
Formulations MTF1 and MTF2 contained 20% and 30% 
concentration of DMG respectively and as shown in the swelling 
studies, MTF3 forms a thicker gel and swelling time was longer 
which resulted in greater drug release reta
MTF3 to MTF6 that had long swelling time also showed high drug 
release retarding effects. 
 (mean±SD, n=3), Key: DMG
 
 
fig. 3 and 4. 
ic regions 
3 and 4, the FTIR 
-H 
stretching vibration of C = N–H groups (3400
1596.3 and 1597.6 cm-1 was shown by metformin and metformin 
plus DMG, respectively, for C = N stretching vibrations (1685
cm-1). A band at 2831.6 and 2831.9 cm
metformin plus DMG respectively representing symmetric CH3 
stretching vibration (2885–2865 cm
(1220–1020 cm-1) representing C
compounds was noted at 1038.8 and 1042.7 cm




 in a longer time 
 
 gum, NaCMC–
rding effect. Formulations 
 
–Detarium microcarpum gum, 
–3100 cm-1). A band at 
–1580 
-1 for metformin and 
-1) was observed. A weak band 
–N vibrations for aliphatic 
-1 for metformin and 
 
Fig. 4: FTIR spectrum of metformin plus 
 
Table 4: Kinetic models for the release o
Kinetic model MTF1 




















Kinetics and mechanism of release 
The predominant kinetics of release of metformin from the 
sustained release matrix tablets, as shown in table 4 was by first
order for all the formulations except for formulation MTF6 where 
the Higuchi model was also prominent. Higuchi model was the 
predominant model for formulation MTF5 though the contribution 
of the first-order model was also prominent. 
The mechanism of release was by non-Fickian or anomalous 
diffusion (0.45<n<0.89) [20]. The drug was released by diffusion 
Okafo et al. 
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Fig. 3: FTIR spectrum of metformin 
 
Detarium microcarpum gum
f metformin from matrix tablets
MTF2 MTF3 MTF4 MTF5 
9.499 10.700 10.790 8.102 
-0.26 0.264 0.313 0.581 
0.136 0.235 0.295 0.115 
0.898 0.944 0.930 0.948 
28.95 32.24 32.49 24.06 
0.724 0.896 0.899 0.955 
0.071 0.076 0.073 0.069 
0.728 0.858 0.875 0.922 
0.621 0.500 0.473 0.460 
0.317 0.414 0.444 0.450 
0.640 0.761 0.795 0.744 
-
through the gel formed as a result of hydration of gum and later 
through erosion of the matrix. 
Stability studies 
There was no significant difference (p 
hardness values for optimized formulation (MTF2) after 
storage at 40±2 °C/75±5% RH as shown on
shown in fig. 5 indicated that there was no change in drug release (p 



















≤ 0.05) in friability and 
3 mo of 
 table 5. The result as 
±2 °C/75±5% RH. 
Table 5: Stability results for formulation MTF2 after 
Formulation code 0 mo 
Friability (%)
MTF2 0.80 
Notes: Hardness data values are expressed as mean
 
Fig. 5: % drug release from formulation MTF2 at 0 and after 
CONCLUSION 
The yield of gum from Detarium microcarpum
(76.39±1.17%w/w). DMG did not show any incompatibility with 
metformin. Matrix tablets of metformin were successfully 
formulated using different concentrations of
microcarpum gum alone or in combination with sodium 
carboxymethylcellulose as polymer matrix former.
Formulations MTF2 (30% DMG), MTF5 (20% DMG and 10% NaCMC) 
and MTF6 (30% NaCMC) were able to sustain the release of 
metformin from the matrix tablets for up to 1
stability studies showed that the formulated tablets were stable.
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